Survival analysis based on SLC4A4 expression in multiple malignancies (including breast cancer, lung cancer, gastric cancer, and ovarian cancer) demonstrated that lower SLC4A4 expression significantly correlated with poorer progression (including OS, RFS, PPS, DMPS, FP or PFS) of patients. The gene discussed is SLC4A4; the disease is lung cancer.